Patritumab: Phase III discontinued

Daiichi discontinued the double-blind, placebo-controlled, international Phase III HER3-Lung trial of IV patritumab after an IDMC concluded the study’s first part

Read the full 212 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE